InvestorsHub Logo

newmedman

08/20/12 4:20 PM

#77299 RE: joaopaulo #77298

because it spells out CBIS recent dealings in detail... You have to look at the exhibits, not just the filings. They are finally outlining a real business plan with their new executives and the deals are now fully disclosed so no more guesswork.

Now we see if the plan comes to fruition or if it was worth it at all imo.

IN WITNESS WHEREOF, the parties have duly executed and delivered this Agreement as of the date first written above.



CANNABIS SCIENCE, INC.

Per: /s/ Robert Melamede
___________________________
Dr. Robert Melamede, President




CONSULTANT:

Per: /s/ Brett Bogue
_______________________________
Brett Bogue

APPENDIX “A”

Consultant’s duties include, but are not limited to the following:

Director of Horticulture:

Develop and Maintain Growing Standards (processed and procedures) for, including but not limited to:
i. the maintaining of healthy mother plants dedicated to cloning and guaranteed to be females.
ii. Cloning, vegetative growth, CBIS extractions, formulations, and analytics.
iii. Utilizing any material from harvest, including stalks and leaves, for use in downstream extracts and formulations.
iv. Growth and maintenance of (proprietary) CBIS transgenic strains generated by the lab division.
v. Growth and maintenance of micropropagated clones generated by the lab division.
vi. Any other responsibilities seen to be properly designated by CBIS in the production of high grade medical marijuana.
vii. Including, but not limited to lights, hydroponic trays and growth pots, water pumps, airflow devices (intake/exhaust), carbon filters, growth media, nutrients, antimicrobials, and any other equipment necessary for the production of hydroponically or soil-grown medical marijuana.

Development of Plants/Strains:
i. Procuring and development of plants and strains for optimal CBIS medical marijuana production.

c. Grow Operations:
i. Design and management of Research and Development facilities.
ii. Setup of equipment.
iii. Manage facility production.

d. Training and Management:
i. Train and oversee various operations staff.

Laboratory/MIPS Facilities/Product Development:
i. Assist with set up of laboratory and product development team member
ii. Assist with laboratory relationships

Manufacture Facilities:
i. Assist with set up of manufacture
ii. Assist with manufacture relationships


IN WITNESS WHEREOF, the parties have duly executed and delivered this Agreement as of the date first written above.



CANNABIS SCIENCE, INC.

Per: /s/ Robert Melamede
___________________________
Dr. Robert Melamede, President




CONSULTANT:

Per: /s/ Mohammed Afaneh
_______________________________
Dr. Mohammad Afaneh






APPENDIX “A”

Consultant’s duties include, but are not limited to the following:

Chief Operating Officer:

Develop and Maintain Operational Growth Standards (processed and procedures) for, including but not limited to:
i. the maintaining of daily operations within the organization. Maintaining of the day to day of the various departments within the organization.
ii. Manage the product development for medical patients for critical ailments and for use in downstream CBIS extractions, formulations, and analytics.

Areas Of Responsibility:

THE MARKET OPPORTUNITIES FOR WHOLE PLANT PHARMACEUTICALS
1. Markets of Interest
a) FDA Track Drug Approval - Nationwide
i. PTSD & Chronic Pain
ii. Additional Indications of Interest
b) States with Approved Medical Marijuana Grow Plans
2. Our Future Product Line: Various Medical Cannabis Preparations
a) Pharmaceuticals - Oral & Topical Containing:
i. Phytocannabinoids
ii. Synthetic Cannabinoids
iii. Hybrids
b) Nutraceuticals - Psychologically Inactive
i. Dietary Supplements, i.e. Hemp-Based Foods
ii. Topical Lotions, Salves, Balms, Creams

Whole Plant Pharmaceutical Products:
i. Psychoactive Medicines (Drugs)
ii. Non-psychoactive Neutroceuticals
iii. Botanical Medicines
iv. Research & Development
v. Formal testing/ Licensing (FDA, State or Federal jurisdictions)
vi. Commercial Licensing
vii. Commercialization (Manufacturing/Production)
viii. Multiple-Market (Countries) Penetration

Delivery Methods:
i. Lozenge
ii. Strips
iii. Cream
iv. Liquid
v. Pills
vi. Extracts

PRIORITIES/MILESTONES
i. Grand Opening of Cannabis Science Executive Offices, as well as cGMP compliant Lab Division, and Production Division, and Extraction Division.
ii. Continued collaboration with our Advisory Boards and Consultation Firms with respect to meeting the highest quality standards in the nation.
iii. Utilizing our quality products in local Colorado randomized, placebo-controlled trials in PTSD and Chronic Pain cohort groups.
iv. Continued investigation and collaboration with several partners in our investigation into the proper route and product for IND application to the FDA, including the possibility of accelerated approval.
v. Further consultations and investigations into US Military and Government contracts to provide cannabis-based medications for our veterans and soldiers.






INDICATIONS OF INTEREST
1. AIDS 2. Alzheimers 3. Anti-Aging 4. Asthma 5. Arthritis 6. Auto Immune Disease 7. Brain Trauma (Closed Head Injury) 8. Cancer 9. Chronic Pain Management 10. Crohn’s, Irritable Bowel Syndrome (IBS) 11. Diabetes 12. Digestive Illnesses 13. Gastro Intestinal Reflux Disease (GERD) 14. Glaucoma 15. High Blood Pressure 16. Influenza 17. Methicillin-Resistant Staphylococcus Aaureus (MRSA) 18. Mutiple Sclerosis (MS) 19. Post Traumatic Stress Disorder (PTSD) 20. Tourette Syndrome

INITIAL TARGET MARKET
United States (USA)
i. FDA Clinical Human Trials: Cancer, PTSD, Influenza
ii. US Military: PTSD, Chronic Pain
iii. Asthma
iv. Arthritis

Development of Plants/Strains:
i. Procuring and development of plants and strains for optimal CBIS medical marijuana production.

d. Grow Operations:
i. Design and management of marijuana grow facilities.
ii. Setup of growing equipment.
iii. Manage plant production.

e. Training and Management:
i. Train and oversee various operations staff.

Laboratory Facilities/Product Development:
i. Assist with set up of laboratory and product development team member
ii. Assist with laboratory relationships

Manufacture Facilities:
i. Assist with set up of manufacture
ii. Assist with manufacture relationships

Dispensary/Clinical Facilities:
i. Manage set up of dispensary and clinical facilities
ii. Manage dispensary and clinical relationships

Marketing/Distribution:
i. Manage set up of marketing and distribution
ii. Manage marketing and distribution relationships
GGECO University:
i. Manage operations
ii. Develop marketing protocols
Television Show Development:
i. Concept development
ii. Distribution agreements


http://www.sec.gov/Archives/edgar/data/1024626/000151712612000161/exhibit101.htm